Overview
STATEMENT OF NEED
Immune thrombocytopenia is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x 109/L with no known cause. The incidence is estimated to be 1.6 to 3.9 per 100,000 patient-years in adults and 0.46 to 12.5 per 100,000 patient-years in children. Research has shown that the burden of ITP is significant. A survey of more than 1,300 patients across 13 countries showed 36% reported a high impact on emotional well-being and 28% on ability to work. Furthermore, nearly two-thirds reported fatigue as the most severe symptom, underscoring the effect of ITP on day-to-day quality of life. Current gaps in knowledge, including the lack of specific diagnostic criteria and uncertainty about the true frequency of bleeding events, limit effective management. In addition, the dearth of prospective trials evaluating new treatment options represents an important unmet need.
TARGET AUDIENCE
Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with immune thrombocytopenia (ITP).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Discuss the pathogenesis of ITP and mechanisms of therapeutic strategies
- Differentiate the efficacy and safety profiles of current and emerging ITP therapies
- Develop evidence-based strategies to optimize treatment experiences and ensure patient-centered ITP care
FACULTY
Allison Miller Imahiyerobo, APN (Chairperson)
Advanced Practice Nurse
Hematology and Oncology Physicians of Englewood
REGISTRATION
There is no fee to participate in or claim NCPD credit for this activity.
Provided by
Nursing Continuing Professional Development
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this NCPD activity. This activity has been designated for 0.6 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of a NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
Allison Miller Imahiyerobo, APN, discloses that she has served as a consultant for Amgen. She has also served on the speakers' bureau for Amgen.
The i3 Health planners and managers have nothing to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
- Take the pretest
- Watch the video
- Pass the posttest with a score of ≥80%
- Complete the activity evaluation
- Download or print their Certificate of Credit
UNAPPROVED USE DISCLOSURE
i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Dova Pharmaceuticals, Inc.
Aggregate participant data will be shared with commercial supporters of this activity.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it.